Meanwhile, the combination of EZH2 inhibitors with proteasome inhibitors to induce tumor regression in vivo [12], and the feasibility of synthetic dual-target inhibitors, has been put on the agenda [19], but there is still insufficient evidence for clinical application. The gene discussed is EZH2; the disease is neoplasm.